Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants.
Sonoma Pharmaceuticals (Formerly Known As Oculus Innovative Sciences, Inc.) (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, today announced the pricing of its public offering of 8,500,000 shares of common stock at a price of $0.20 per share. The gross proceeds of the offering to the Company, before deducting placement agent fees and commissions and estimated offering expenses, are expected to be approximately $1.7 million. The offering is expected to close on or about October 30, 2023, subject to customary closing conditions.
Maxim Group LLC is acting as the sole placement agent in connection with the offering.
The offering is being conducted pursuant to the Company’s registration statement on Form S-1 (File No. 333-274582) previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”) on October 26, 2023. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Copies of the final prospectus relating to this offering, when available, may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands.
More information can be found at www.sonomapharma.com.
Does your company have business or financial objectives?
If your company has business or financial objectives, check out the advisory services for growing global technology companies provided by FC Global Strategies.
Our calendar link to schedule a call.
Jeffrey Friedland - Based in the U.S.
(North America and Global)
+1 646 450 8909
Ross Swan -Based in Singapore
(Southeast Asia, Australia, Asia-Pacific)
+65 9181 9472
David Krutonog - Based in Israel
(Eastern Europe, Middle-East and North Africa)
+972 50 974 3429
Claudio Hebling - Based in Brazil
+55 19 99377 7482
Vincent Paul Joseph - Based in India
(South Asia, India, Sri Lanka)
+91 962 620 9090